Coronary artery disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PCSK9 14
• SGLT2 12
• APOE 0
• GLP-1 4
• NLRP3 1
• PPAR 0
• IL-6 2
• NRF2 0
• CD40 0
• AKT 0
• VEGF 0
• TNF 1
• PI3K 0
• SIRT1 0
• TP53 0
• HMGB1 0
• STAT3 0
• TLR4 0
• HIF-1 0
• AMPK 0
• IL-1 1
• JAK 0
• MMP-9 0
• STING 1
• ACE2 0
• ERK 0
• GIP 1
• mTOR 0
• PD-1 0
• BDNF 0
• COX-2 0
• CXCR4 1
• DPP-4 0
• FGFR 0
• HER2 0
• IL-17 1
• MAPK 0
• PTEN 0
• TREM2 0
• YAP 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APP 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BTK 0
• CCR5 0
• CGRP 0
• CTLA-4 0
• CTNNB1 0
• EZH2 0
• FOXP3 0
• FTO 0
• G6PD 0
• GPX4 0
• HSP90 0
• IL-4 1
• LRRK2 0

EU-13 is a filter, not a ranking: it only narrows the list.

12 of 12+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

  NCT05613426· Henan Institute of Cardiovascular Epidemiology· Updated 22 May 2026

  “Slow patient enrollment and lack of financial support”Registry text, quoted unchanged. Source

• Withdrawn

  Immunomodulatory Effects of PCSK9 Inhibition

  NCT05720156· Massachusetts General Hospital· Updated 26 Sept 2025

  “Lack of Feasibility”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Novartis Pharmaceuticals· Source

• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

  NCT05360446· Novartis Pharmaceuticals· Source

• A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma

  NCT07803679· Amgen· Source

• Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

  NCT05192941· Novartis Pharmaceuticals· Source

• Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography

  NCT06863545· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)

  NCT06791031· West China Hospital· Source

• Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

  NCT07084259· Hanyang University Seoul Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 14
• Organoids 1
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 4
• Gene Expression Profiling 48
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 68
• Metabolomics 41
• Mass Spectrometry 5
• Flow Cytometry 26
• Immunohistochemistry 12
• Positron-Emission Tomography 64
• Magnetic Resonance Imaging 66
• Machine Learning 161
• Deep Learning 85
• Cohort Studies 404
• Genome-Wide Association Study 163

• Adjusting for Medication Use in GWAS and Its Impact on Mendelian Randomisation Analyses: An Example of Systolic Blood Pressure in UK Biobank.

  Genet Epidemiol, Dec 2026

• Identification of genetically supported candidate therapeutic targets for angina pectoris using mendelian randomization.

  Medicine (Baltimore), Oct 2026

• Gut microbiota, sleep and coronary artery disease: A Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Blood proteome-wide Mendelian randomization reveals molecular pleiotropy in coronary artery disease.

  Atherosclerosis, Oct 2026

• Genetic factor analysis for characterizing phenome-wide patterns of genetic pleiotropy.

  Nat Genet, Sept 2026

• Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization.

  Hypertension, Sept 2026

• Exploring the role of gut microbiota in coronary atherosclerosis through lipoprotein-mediated cholesterol transport and distribution: A Mendelian randomization analysis.

  Medicine (Baltimore), Sept 2026

• The Omnicausal Model Reveals the Highly Polyfactorial Nature of Complex Diseases.

  Genet Epidemiol, Sept 2026

• Context-Stratified Mendelian Randomization: Exploiting Regional Exposure Variation to Explore Causal Effect Heterogeneity and Nonlinearity.

  Stat Med, Sept 2026

• Myeloid Dendritic Cell Counts and Coronary Heart Disease: a Bidirectional Mendelian Randomization Study.

  Clin Lab, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.